Literature DB >> 24038885

How long can folinic acid rescue be delayed after high-dose methotrexate without toxicity?

Ian Joseph Cohen1, Johannes E Wolff.   

Abstract

To determine the optimal time of folinic acid rescue after methotrexate (MTX) treatment in patients with ALL, we selected and evaluated relevant studies that included doses, rescue delay, and side effects. Rescue at 42-48 hours resulted in considerable toxicity, except when low doses of MTX were used (1 g/m(2)) or serum MTX levels remained consistently low at 24, 30, and 36 hours. Rescue started at 30-36 hours was safe. In the absence of evidence that later rescue improves prognosis, we suggest that folinic acid rescue (105 mg/m(2)) be started no later than 36 hours from the start of MTX (5-6 g/m(2)).
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  dose; folinic acid; leucovorin rescue; methotrexate; timing

Mesh:

Substances:

Year:  2013        PMID: 24038885     DOI: 10.1002/pbc.24770

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  10 in total

1.  Reply to: methotrexate administration directly into the fourth ventricle in children with malignant fourth ventricular brain tumors: a pilot clinical trial.

Authors:  Ian J Cohen
Journal:  J Neurooncol       Date:  2016-01-05       Impact factor: 4.130

2.  Tolerability and pharmacokinetics of disodium folinate following single intravenous doses in healthy Chinese subjects: an open-label, randomized, single-center study.

Authors:  Yani Liu; Jiali Zhou; Zhongfang Li; Chunxiao Yang; Jianhong Wu; Yu Zhang; Shaojun Shi; Yunqiao Li
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-08-31       Impact factor: 2.441

3.  Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.

Authors:  M A H den Hoed; E Lopez-Lopez; M L te Winkel; W Tissing; J D E de Rooij; A Gutierrez-Camino; A Garcia-Orad; E den Boer; R Pieters; S M F Pluijm; R de Jonge; M M van den Heuvel-Eibrink
Journal:  Pharmacogenomics J       Date:  2014-11-04       Impact factor: 3.550

Review 4.  Mechanisms, Management and Prevention of Pemetrexed-Related Toxicity.

Authors:  Nikki de Rouw; Berber Piet; Hieronymus J Derijks; Michel M van den Heuvel; Rob Ter Heine
Journal:  Drug Saf       Date:  2021-11-06       Impact factor: 5.606

5.  Development and Validation of UHPLC-MS/MS Assay for Therapeutic Drug Monitoring of High-dose Methotrexate in Children with Acute Lymphoblastic Leukemia.

Authors:  Le-Jing Lian; Bin Lin; Xiao Cui; Jie He; Zhe Wang; Xiao-Dong Lin; Wei-Jian Ye; Rui-Jie Chen; Wei Sun
Journal:  Drug Des Devel Ther       Date:  2020-11-10       Impact factor: 4.162

6.  Disparate Response to Methotrexate in Stem Versus Non-Stem Cells.

Authors:  Olivia S Beane; Louise E O Darling; Vera C Fonseca; Eric M Darling
Journal:  Stem Cell Rev Rep       Date:  2016-06       Impact factor: 5.739

7.  Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway.

Authors:  Vasanthi S Viswanathan; Matthew J Ryan; Harshil D Dhruv; Shubhroz Gill; Ossia M Eichhoff; Brinton Seashore-Ludlow; Samuel D Kaffenberger; John K Eaton; Kenichi Shimada; Andrew J Aguirre; Srinivas R Viswanathan; Shrikanta Chattopadhyay; Pablo Tamayo; Wan Seok Yang; Matthew G Rees; Sixun Chen; Zarko V Boskovic; Sarah Javaid; Cherrie Huang; Xiaoyun Wu; Yuen-Yi Tseng; Elisabeth M Roider; Dong Gao; James M Cleary; Brian M Wolpin; Jill P Mesirov; Daniel A Haber; Jeffrey A Engelman; Jesse S Boehm; Joanne D Kotz; Cindy S Hon; Yu Chen; William C Hahn; Mitchell P Levesque; John G Doench; Michael E Berens; Alykhan F Shamji; Paul A Clemons; Brent R Stockwell; Stuart L Schreiber
Journal:  Nature       Date:  2017-07-05       Impact factor: 49.962

8.  DHFR-mediated effects of methotrexate in medulloblastoma and osteosarcoma cells: the same outcome of treatment with different doses in sensitive cell lines.

Authors:  Jakub Neradil; Gabriela Pavlasova; Martin Sramek; Michal Kyr; Renata Veselska; Jaroslav Sterba
Journal:  Oncol Rep       Date:  2015-02-26       Impact factor: 3.906

9.  Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen.

Authors:  Gaganpreet S Tiwana; Remko Prevo; Francesca M Buffa; Sheng Yu; Daniel V Ebner; Alison Howarth; Lisa K Folkes; Balam Budwal; Kwun-Ye Chu; Lisa Durrant; Ruth J Muschel; W Gillies McKenna; Geoff S Higgins
Journal:  Oncotarget       Date:  2015-03-20

10.  Medication Error- A Case Report of Misadventure with Methotrexate.

Authors:  Anup Singh; Aru Chhabra Handa
Journal:  JNMA J Nepal Med Assoc       Date:  2018 Mar-Apr       Impact factor: 0.406

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.